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New candidates for development as potential drugs or virucides against HIV-1 infection and AIDS continue to be needed. The HIV-1 RNA
leader sequence has many essential functional sites for virus replication and regulation that includes several highly conserved sequences. The
review describes the historical context of targeting the HIV-1 RNA leader sequence with antisense phosphorothioate oligonucleotides, such as
GEM 91, and goes on to describe modern approaches to targeting this region with steric blocking oligonucleotide analogues having newer and
more advantageous chemistries, as well as recent studies on siRNA, towards the attainment of antiviral activity. Recent attempts to obtain
improved cell delivery are highlighted, including exciting new developments in the use of peptide conjugates of peptide nucleic acid (PNA) as
potential virucides.
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HIV-1 infection continues to spread at an alarming rate. In
2004, some 5 million new cases of infection worldwide were
reported (http://www.unaids.org/wad2004/EPIupdate2004_
html_en/epi04_02_en.htm). This demonstrates the current1758 (2006) 290 – 300
http://www
J.J. Turner et al. / Biochimica et Biophysica Acta 1758 (2006) 290–300 291inability to control viral spread. The lack of a suitable and
widely applicable vaccine or other effective control measure
means that the only weapons available to combat HIV-1
infection and AIDS are a combination of anti-retroviral agents
(HAART, highly active anti-retroviral therapy) or virucidal
agents that can be used in topical formulation for use during
sexual contact, which is the main route of new infections.
Unfortunately, no topical virucides have yet been approved for
clinical use and sadly HAART is still only able to reach a small
fraction of those that are infected. Nevertheless, new anti-
retroviral agents continue to emerge [1,2]. There is a pressing
need to find new anti-HIV-1 agents and combinations that are
more effective, better tolerated, cheaper, and which may also
have virucidal activity suitable for worldwide use.
Intense efforts are being made to understand the complex
steps in the HIV-1 replication cycle. Almost all of these steps
and gene products represent potential targets for the develop-
ment of inhibitors, yet most clinically available drugs are small
molecules aimed at only a very limited number of such targets,
predominantly the viral proteins reverse transcriptase (RT) and
protease. There are numerous other molecular strategies that
are being investigated to interfere with virus replication
(reviewed in [3]) many of which are aimed at gene therapy
(reviewed in [4]). These include HIV-1 RNA targeting
strategies such as antisense RNA, ribozymes, decoy RNAs
(mimics of known RNA structures), aptamers (selected
sequences that recognise RNA structures) and small interfering
RNA (siRNA), as well as protein-based techniques such as
transdominant negative proteins, nucleases, single-chain and
whole antibodies. The aim is to deliver such reagents to
haematopoietic progenitor cells to protect their differentiated
progeny from HIV-1, to render HIV-1-susceptible cells resistant
to HIV-1 infection, to inhibit HIV-1 replication in cells and in
discrete organ target sites, or to immunize against HIV-1 for
treatment or prophylaxis. An advantage of gene therapy is that
there is an inherent and consistent antiviral protection main-
tained against virus challenge, whereas with pharmacotherapy
a patient must take anti-retroviral drugs regularly to maintain
sufficient therapeutic action. However, gene therapy
approaches are unlikely to be applicable to a large enough
number of patients worldwide to meet the perceived needs and
may have safety issues.
Many of the RNA sequences that are considered targets in
gene therapy and the entities that interact with them (proteins
and other RNAs) are also potential targets for anti-HIV-1 drug
development. The genome of HIV-1 is small (about 9000
nucleotides) [5] and hence molecular function is packed
densely into the RNA sequence, with functionality sometimes
overlapping or coincident. Although much of the RNA
sequence is able to mutate rapidly (because of the infidelity
of the HIV-1 RT during replication) and thereby gain resistance
to drug action, a few highly functional regions have short
sequences that are well conserved between viral isolates and
rarely or never mutated. The HIV-1 RNA leader sequence is
particularly rich in such functional elements.
Synthetic oligonucleotides and their analogues complemen-
tary to HIV-1 RNA have great potential for the sequence-specific targeting of functional RNA elements as probes for
understanding the molecular biology of HIV-1 and for
development of possible antiviral or virucidal agents. We
review here the various oligonucleotide-based strategies that
are currently under study and point to some recent exciting
results in targeting the HIV-1 RNA leader sequence where
antiviral and virucidal activities within cell culture assays have
been attained. We also discuss some of the challenges of
developing oligonucleotides as potential anti-HIV-1 therapeu-
tics, particularly in obtaining efficient cell delivery. A more
general review on antiviral activities of oligonucleotides has
been published recently [6].
2. Targets in the HIV-1 RNA leader sequence
There are three classes of RNA produced during the
expression of the HIV-1 proviral genome. The shortest class
(¨2 kb) are doubly spliced transcripts that are produced early
in gene expression coding for the regulatory genes tat, rev and
nef. Later in expression, a singly spliced transcript (¨4 kb)
encoding the genes for structural proteins env, vif, vpr and vpu
is seen. Finally, full-length unspliced RNA (¨9 kb) coding for
gag/pol, leading to expression of the viral enzymes is
produced. This acts also as the genomic RNA that is dimerized
and incorporated into the HIV-1 virion. All of these RNAs
contain the first 290 residues of RNA, up to the first splice
donor (SD) site, which includes several functional sites that are
important at distinctive stages of the viral replication cycle.
Full-length genomic and partially spliced RNAs contain also
additional essential sites in the next 50-nucleotide stretch
including the initiator AUG of gag.
A model of secondary structure of the RNA leader
sequence, based on phylogenetic and in vitro conformational
studies, shows that the functional sites are commonly, but not
exclusively, located within apical loop regions [7–9] (Fig. 1).
The region of the HIV-1 genome between the Poly(A) loop and
the primer binding site (PBS), known as U5 is thought to form
a duplex with the AUG region [9]. Although the secondary
structures of the first two stem–loops, the trans-activation
responsive element TAR and the Poly(A) site, are well
established, there are alternative folding proposals for other
parts of the RNA leader sequence, for example the region
including the dimerization initiation site (DIS), SD and
packaging signals (psi, c) [10]. Models that involve longer
distance interactions have also been presented, such as an
alternative helix between the poly(A) site and the DIS
sequences [11]. Of particular importance is that RNA structures
alter as a result of interaction with proteins (e.g., the interaction
of psi with the Gag protein [10]) or with other RNA (e.g., the
PBS region with tRNALys3 that occurs during initiation of
reverse transcription [12]).
2.1. The trans-activation responsive element TAR
The most well-studied region of the HIV-1 leader RNA is
the extreme 5V-end 59-residue stem–loop, the trans-activation
responsive element TAR (Fig. 2). The apical part of TAR acts
Fig. 1. Secondary structure schematic model of the HIV-1 leader sequence
showing the regions of functionality and the sites of interaction of an early anti-
HIV-1 oligonucleotide [30] and the clinically investigated phosphorothioate
oligonucleotide GEM 91 [36].
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some host cellular factors that together form a complex that
triggers a massive boost in transcriptional elongation by
stabilization of the transcription complex as it passes through
the TAR region [13,14]. Both Tat and TAR are also thought to
play a role in initiation of reverse transcription [15]. The apical
loop and stem is highly conserved between viral isolates. Since
Tat trans-activation is essential for viral replication, inhibitors
of Tat or TAR have been sought for many years, Sadly, despite
the numerous small molecule inhibitors that have been
discovered (reviewed in [16]), no clinical anti-HIV-1 candi-
dates have emerged. Many such inhibitors prove not to have
TAR-binding specificity in cells or their antiviral activity is
subsequently found not to correlate with TAR binding or Tat-Fig. 2. Sequence and secondary structure model of the HIV-1 TAR element
(subtype B, LAI strain) showing the region targeted by synthetic
oligonucleotides.dependent trans-activation inhibition. However, the TAR
stem–loop has been an important target for oligonucleotide-
based approaches since the early 1990s where it has been found
that a high level of target binding specificity can be obtained
[17].
2.2. The primer-binding and dimerization initiation sites
Another much studied region is the initiation site for reverse
transcription. Following the essential enabling interaction
between the 3V-end of the host tRNALys3 and the PBS, there
are rearrangements of the RNA structure involving additional
interactions with other nearby regions (pre-PBS) such that the
conformation of the RNA is radically altered [12] (Fig. 3). Not
surprisingly, because of the 18-nucleotide PBS–tRNA inter-
action, the PBS sequence is highly conserved and thus has been
an obvious target for oligonucleotides for the blocking of the
initiation of reverse transcription, since the early 1990s [18]
and as an anti-HIV-1 agent as far back as 1989 [19].
The DIS was identified as a stem–loop structure that is self-
complementary and forms a loop–loop Fkissing complex_ as a
first step in the dimerization mechanism [20,21] (Fig. 4).
Oligonucleotides in both antisense and sense forms were
shown to form complexes with the DIS site, thus opening up
alternative strategies for inhibition [22]. There is strongFig. 3. Sequence and secondary structure model of the pre-PBS, PBS and par
of the U5 region in the folded conformation believed to be present afte
formation of the RNA–tRNALys3 reverse transcription initiation complex [11]
The 18-nucleotide sequence complementary to the 3V-end of the tRNA and
highly conserved between viral isolates is boxed.t
r
.
Fig. 4. Sequence and secondary structure model of the dimerization initiation
site DIS (subtype A, MAL strain and subtype B, LAI strain).
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genomic RNA. However, the DIS loop sequence varies
between viral isolates and thus, for example, homologous
oligonucleotides display vastly different dimerization inhibi-
tion efficiencies between two strains that differ only modestly
[23]. Nevertheless, oligonucleotides targeting this site have
been shown to inhibit HIV-1 replication [24].Fig. 5. Sequence and secondary structural model according to Zeffman et al. [9] of th
site (DIS), SL2 (the splice donor, SD), SL3 (the psi region) that is targeted by oligon
AUG region (when not base-paired to the U5 region).2.3. The major HIV-1 packaging signal
The major HIV-1 packaging signal c has been shown to fold
in vitro into an extended stem–loop structure that contains
three arms (Fig. 5). SL1 is the DIS stem–loop, SL2 stem–loop
contains the major splice donor and SL3 is the major site for
Gag interaction. Gag binding leads to an alteration of the RNA
structure [10]. Use of high affinity oligonucleotides has helped
to map Gag binding to the SL3 loop (Brown, D., Gait, M.J. and
Lever, A., manuscript submitted). In addition, such oligonu-
cleotides have been shown to elicit antiviral activity [25]. The
overlapping nature of functionality in the HIV-1 leader is
exemplified well in that the HIV-1 Rev protein, which binds
primarily to an RNA structure known as the Rev Responsive
Element within the env gene, also binds to a purine-rich loop in
the SL1 region [26].
2.4. Mapping of accessible sites on the HIV-1 RNA leader
Throughout the viral cycle, it is very likely that RNA
conformation alters significantly and thus accessibility to a
particular RNA site would be expected to vary depending on
the virus stage. Particularly little is known about the RNA
structure in HIV-1 virions [27], where the RNA is both
dimerized and complexed with other proteins such as reverse
transcriptase, integrase and nucleocapsid as well as other
structural proteins. Furthermore, there may be sites in the virion
RNA that are occluded because of interactions, such as the PBS
with tRNA and the DIS because of RNA dimerization.
Therefore, in practice, the availability of any particular RNAe major HIV-1 packaging signal region including SLI, the dimerization initiation
ucleotides designed to block Gag binding [25], and a possible stem–loop at the
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during HIV-1 infection cannot be predicted with reliability and
must be tested by experiment.
An interesting approach to identifying accessible target sites
for antisense oligonucleotides in highly structured RNA such
as the HIV-1 leader has been developed, whereby a 20-mer
library of RNA fragments generated from the HIV-1 genome is
used as a probe for RNA binding and inhibition of dimerization
[28]. Five distinct sites were identified, namely in the poly(A),
PBS, DIS, SD and AUG regions. Surprisingly no sites in TAR
or psi were found by this hybridization method employed,
which may be because of biases introduced by use of a single
20-mer length. Strand invasion of highly structured RNAs is
dependent on many complex factors, such that an increase in
probe length does not always correspond to better RNA
binding. Strand invasion of TAR, for example, is best
accomplished by shorter oligonucleotides that lead to a
pseudo-half knot structure [29]. Another limitation is that the
conformations adopted by in vitro transcribed HIV-1 leader
RNA may be different to those that actually occur in the viral
cycle. In future, mapping of the HIV-1 RNA in the virion will
be needed. Nevertheless, a library hybridization approach is a
useful starting point to identify vulnerable RNA structures and
it is now clear that several sites of essential functionality within
the HIV-1 leader are also sites of good invasion by
oligonucleotides [25].
3. Oligonucleotide-based RNA-targeting approaches
3.1. RNase H-active antisense oligonucleotides
The concept of an oligonucleotide targeting HIV-1 RNA as
a therapeutic agent is almost 20 years old [30]. The first
experiments utilized 12–26 long unmodified oligodeoxyribo-
nucleotides that were targeted just upstream of the PBS (Fig.
1), in a region we now know to be structurally altered when the
tRNALys3 binds [12]. The oligonucleotides showed inhibition
of HIV-1 growth when added at high (20 AM) concentrations to
either peripheral human blood lymphocytes or transformed T-
cells at the same time as virus. Unmodified oligodeoxynucleo-
tides are unstable to serum and cellular nucleases andFig. 6. Nucleotide analogues used insignificant improvements to activity were found when the
oligonucleotide backbone was changed to phosphorothioate
(PS) (Fig. 6), which has much higher stability to nucleases.
This analogue is one of the very few that permits recognition of
an oligonucleotide/RNA hybrid by RNase H that results in
RNA cleavage. The first evidence that such a mechanism might
operate in cells when an oligonucleotide is used to bind to
mRNA was just becoming known at this time [31].
Virus inhibitory activity could be elicited at much lower
concentrations (1 AM) with phosphorothioates than unmodified
oligodeoxynucleotides in both simultaneous oligonucleotide
addition/ HIV-1 infection models (acute infection) and in
chronically infected cell models (where the virus has already
integrated its genome into the host) [32]. Sequence specificity
of inhibition was much higher in the chronic than in acute
models, since for example a dC28 oligonucleotide was just as
effective in an acute model [33].
Although many different sites on the HIV-1 genome were
investigated over the following years and a number of
preclinical oligonucleotide candidates developed, the only
oligonucleotide to enter clinical trials was a 25-mer PS
oligodeoxynucleotide, named GEM 91, targeted to the AUG
initiator site of the Gag protein [34–36] (Fig. 1). Interestingly,
this site is identical to one of the five selected recently by 20-
mer library scanning of the HIV-1 leader RNA, a point not
commented on by these authors [28]. The target sequence is
highly conserved between viral isolates and GEM 91 was
found to be very effective in long term culture using primary
blood lymphocytes and macrophages infected with HIV-1
obtained from some patient isolates at 1 AM and at higher
concentrations with chronically infected cell lines [34,36].
Viral escape in long term culture of up to 3 months was not
seen [34]. Although GEM 91 was well tolerated by patients in
Phase I studies, there were some side effects of thrombocyto-
penia, elevation of transaminases and prolongation of activated
partial thromboplastin time. Another problem was a relatively
short half-life in serum that necessitated extended i.v. perfusion
treatment. Sadly, lack of efficacy forced the withdrawal of
GEM 91 from later clinical trials.
GEM 91 was shown in 1997 to have multiple inhibitory
mechanisms [37]. Sequence-dependent inhibition of virusantisense oligonucleotide studies.
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some effect on the steady state RNA levels. Sequence-
independent effects were also seen of inhibition of virion
binding and inhibition of virus production. The non-sequence
specific inhibition of virus absorption was shown to play a
predominant role in the total antiviral activity due to a
polyanionic effect of the phosphorothioate backbone, similar
to dextran sulfate. Steady state Gag mRNA levels, for
example, dropped only 3-fold in treatment of chronically
infected cells with 1 AM GEM 91, but p24 production was 10-
fold lower [37]. This suggests that intracellular RNase H
cleavage by GEM 91 is at best inefficient. This is not
surprising since it had been shown clearly that free uptake of
GEM 91 PS oligonucleotide was almost exclusively restricted
to endosomal vesicles within the cytosol, for example in
MOLT-3 cells [36]. By 1992, it had been shown that good
delivery of PS oligonucleotides into cells in culture required
formulation with cationic lipids for efficient nuclear delivery
and such delivery induced a much higher antisense activity
[38]. The RT enzyme also has an RNase H activity and it is
likely that the effects of GEM 91 on reverse transcription
might partly have been due to this [18] as well as to non-
specific phosphorothioate inhibition of the RT template–
primer complex formation [39].
Anazodo et al. noticed a more than 10-fold potentiation of
antisense inhibition effects of a 20-mer PS oligodeoxynucleo-
tide targeted to the extended stem of the DIS site when cells
were pretreated with oligonucleotide/lipid formulation for 24
h [40]. Protection of MT-2 cells from the cytopathic effect of
HIV-1 by the oligonucleotide in the absence of lipid
transfection required 1 AM concentration. An anti-TAR 26-
mer PS oligodeoxynucleotide, long enough to invade the
extended TAR stem, inhibited viral replication in both acute
and chronically infected models, but without sequence spec-
ificity [17]. Despite the widespread use of cationic lipids in cell
culture experiments with synthetic oligonucleotides to enhance
delivery and promote specificity, clinical trials proceeded with
PS oligonucleotides in the belief that in vivo special cell uptake
mechanisms may operate.
Improved versions of GEM 91 were studied later, that
involved a phosphorothioate gapmer approach (mixed back-
bone oligonucleotides) where the flanking nucleotides are
composed of 2V-O-methylnucleotides (OMe) (Fig. 6) but the
central core maintained as deoxynucleotides (GEM 92). Such
second-generation oligonucleotides maintain the ability to
induce RNA cleavage by RNase H, yet are more greatly
protected against degradation by serum and cellular nucleases,
and also have higher RNA binding. Mixed backbone oligonu-
cleotide gapmers carrying nucleoside sugar-modified nucleo-
tides in the arms, in addition to the uniform PS backbone, have
largely supplanted standard phosphorothioates for most appli-
cations and clinical trials [41,42]. However, no second
generation and only a single first generation antisense
oligonucleotide, for the treatment of CMV-induced retinitis in
AIDS patients, have been clinically approved. For HIV-1
treatment, no clinical trial of an oligonucleotide is currently in
progress.Recently, a DNA oligonucleotide targeted to the DIS, where
a section of the oligonucleotide had been modified by tight
RNA-binding locked nucleic acid (LNA) nucleotides (Fig. 6)
but which still directs RNase H cleavage, showed a modest
inhibition of HIV-1 replication using a p24 immunoassay [24].
3.2. Steric block oligonucleotides targeted to HIV-1 RNA
Oligonucleotides that induce RNase H cleavage suffer from
the disadvantage that binding to an incorrect RNA sequence
may nevertheless induce cleavage, leading to the possibility of
off-target mRNA inhibition effects. Such unwanted cleavage of
a non-targeted RNA might lead to cellular and hence
physiological side-effects. By contrast, oligonucleotides that
merely bind an RNA target are much less likely to show off-
target RNA inhibition effects, since incorrect binding will be
generally of no biological consequence, although stoichiomet-
ric quantities are clearly needed for the desired activity.
The blocking of HIV-1 reverse transcription by oligodeox-
yribonucleotides complementary to the region adjacent to the
PBS (pre-PBS) or U5 region was shown many years ago [18].
This could be achieved efficiently for mutant HIV-1-RT
lacking the RNase H activity in the case of the U5
oligonucleotide, but the pre-PBS oligonucleotide required a
primer to bind to PBS, to alter the RNA conformation,
similarly to the binding of tRNALys3, and here an intact RNase
H domain was also needed. Both oligonucleotides, when
conjugated to poly-l-lysine, showed inhibition of HIV-1
infection in MOLT-4 cells in culture in the submicromolar
range and it was shown that blockage was occurring at the level
of proviral DNA synthesis [43].
Steric block oligonucleotide analogues containing uniform
nucleotide modifications that cannot elicit RNase H activity,
for example OMe/PS oligonucleotides, have been investigated
as antisense agents to block translation by binding to the 5V-cap
or AUG sequences in mRNA [44,45]. Potent effects in
inhibition of translation of endogenous genes have been
reported in cells by oligonucleotides complexed with cationic
lipids [46]. More recently, steric block oligonucleotides having
a variety of chemically modified backbones have found wide
application for redirection of splicing pathways in cell nuclei
by binding to intron–exon boundaries (reviewed in [47]).
Several such steric blocking agents have been found to be
active in altering splicing patterns in mice [48,49]. In addition,
a steric block N3V–P5V-phosphorothioamidate (Fig. 6) oligo-
nucleotide targeted to telomerase RNA has entered clinical
trials [50].
In 1989, steric block 21-mer OMe/PS oligonucleotides
targeted to the HIV-1 PBS or splice acceptor site were reported
to block the cytopathic activity of freshly infected MOLT-4
cells, but the authors failed to see activity in a chronically HIV-
1-infected cell model [19]. The detrimental effect of PS
inclusion in 2V-O-methyloligonucleotides on binding RNA is
exemplified well in the 10-fold drop seen in TAR binding
experiments for 17-mers [29]. Such poor binding to structured
RNAs may explain why little antisense activity is observed
with PS/OMe oligonucleotides targeting the HIV-1 leader,
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we have shown by confocal microscopy that fluorescently
labelled 2V-O-methyloligonucleotides lacking PS linkages are
much more poorly taken up by HeLa cells in culture in the
presence of cationic lipids than those with PS linkages or
containing LNA [51]. Probably, the PS linkages or LNA
additions help interactions with lipids or membranes. 2V-O-
methyloligoribonucleotides without such additional modifica-
tions also have insufficient stability to serum nucleases to be
considered for in vivo therapeutic use, although they are
sufficiently stable for cell culture. Nevertheless, 20-mer 2V-O-
methyl oligonucleotides were found to act as competitive
inhibitors of tRNALys3 in binding to the PBS and also showed
significant inhibition of HIV-1 infectivity in a HeLa P4 cell line
expressing CD4 receptors and the lacZ gene under the control
of HIV-1 LTR [52]. 2V-O-methyl, N3V–P5V-phosphoramidate
and peptide nucleic acid (PNA) (Fig. 6) steric block 16-mer
oligonucleotides targeted to TAR (Fig. 2) were shown to be
much more efficient at sequence-specific inhibition of reverse
transcription than unmodified oligonucleotides with IC50 in the
nM range [53]. Such oligonucleotides did not bind non-
specifically to HIV-1 reverse transcriptase, in contrast to a PS
oligonucleotide.
Mixmer steric block oligonucleotides containing OMe and
locked nucleic acid units (LNA) have even higher binding to
TAR RNA than OMe alone and showed sequence specific
inhibition of in vitro Tat binding and Tat-dependent in vitro
transcription [54,55]. A 16-mer OMe/LNA mixmer showed
sequence-specific inhibition of Tat-dependent trans-activation
in a HeLa cell reporter system involving stably integrated
luciferase plasmids with IC50 of 120 nM when delivered by
cationic lipids [51,56]. More recently, this oligonucleotide, and
another similarly composed OMe/LNA mixmer targeted to the
SL3 loop recognised by Gag protein, showed sequence-specific
inhibition of syncitia formation induced by HIV-1 infection in a
HeLa T4 LTR-h-galactosidase model, again when delivered by
cationic lipids [25]. The introduction of LNA units into the
steric block OMe oligonucleotide enhances nuclear delivery
[51] as well as resistance to nucleases. Some inhibition of
trans-activation in a transient cell reporter assay has also been
obtained with OMe oligonucleotides targeted to TAR that
contain some methylphosphonate linkages [57].
Key to the possible use of steric block oligonucleotides as
anti-HIV-1 agents is to be able to enhance free cellular uptake
and delivery. An interesting approach is prefaced by the early
discovery that poly-l-lysine conjugates of oligonucleotides
were delivered into HIV-1-infected cells [43]. These studies
developed into the concept of using one of a number of cell-
penetrating peptides (CPP) as conjugates to oligonucleotides to
enhance their delivery (reviewed in [58–60]). This subject has
been controversial as to the mechanisms of uptake of such
peptides and how their use might lead to the internalization of
attached cargoes. Few examples of significant intracellular
activity have been documented for peptide conjugates of
negatively charged oligonucleotides following free delivery
[61]. We found recently that CPP conjugates of a fluorescein-
labelled, 12-mer OMe/LNA oligonucleotide targeted to TARwere trapped in endosomal compartments of HeLa cells
following free delivery and accordingly were unable to inhibit
Tat-dependent trans-activation in a HeLa cell assay involving
stably integrated luciferase plasmids [62]. By contrast, we have
found recently that certain CPPs (for example, Transportan and
R6-Penetratin) disulphide-linked to a 16-mer PNA targeted to
TAR were able to elicit significant inhibition on free delivery
for 24 h in the HeLa cell trans-activation assay [63]. We
showed also that in general fluorescently labelled CPP-PNA
conjugates are trapped in endosomal or membrane-bound
compartments and their release (and subsequent trans-activa-
tion inhibition activity) can be enhanced by co-administration
of the lysosomotropic agent chloroquine.
Sequence-specific targeting of the PBS and TAR regions of
HIV-1 by PNA to block reverse transcription was established
several years ago [53,64]. Inhibition of Tat-dependent trans-
activation in cell culture with transiently transfected plasmids
[65] and of HIV-1 replication [66] was then achieved by
electroporation of 16-mer PNA into cells in the laboratory of
Pandey. A particularly important discovery was made in which
a disulphide-linked conjugate of 16-mer PNA with the CPP
Transportan was able to elicit anti-HIV-1 activity in chronically
infected CEM or Jurkat cells by free delivery at 1 to 5 AM
concentrations [67]. An even more exciting recent development
was that in addition to its antiviral activity this Transportan-
PNA conjugate (rather similar to the conjugate that we have
been investigating [63]) has very high activity (IC50 66 nM) as
a virucidal agent by pre-treatment of HIV-1 virions before cell
infection [68]. The conjugate has been shown to inhibit reverse
transcription within virions at 500 nM, which may account for
part of this activity. Similar levels of virucidal activity were
found for several other CPP conjugates of the 16-mer PNA, but
their antiviral activities varied significantly from 700 to 1100
nM IC50 [69]. At present, there is insufficient evidence to know
how efficiently such CPP-PNA conjugates enter virions or
whether part of the virucidal activity can be explained by
blocking of virus uptake into cells or some other effect on
infectivity of pretreated HIV-1 virions. Effective virucidal
agents are badly needed and this approach has fascinating
prospects in this respect and thus merits further virological
studies.
3.3. Aptamers targeted to HIV-1 RNA loops
Loop–loop interactions are well known structural features
within folded RNAs and also form the basis of the dimerization
of HIV-1 RNA [22]. A novel approach to oligonucleotide-type
reagents that can bind specifically to HIV-1 RNA has been
described based on the in vitro selection from oligonucleotide
libraries of Faptamers_ that recognise the apical loop of TAR.
Both RNA aptamers [70] and DNA aptamers [71] were first
selected. Such aptamers have remarkable specificity for the
TAR RNA apical loop sequence, even more than the equivalent
antisense oligonucleotides. More recently, chemically modified
DNA aptamers containing N3V–P5V-phosphoramidates [72] or
LNA residues [73] have been selected that have much tighter
binding to TAR and much better serum nuclease resistance.
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biological assays and as anti-HIV-1 agents.
3.4. Short interfering RNA (siRNA)
RNA interference is a natural cell mechanism for control of
gene expression and is induced in particular as a defensive
response to long double-stranded RNA. One part of the RNA
interference pathway has been utilized for mRNA degradation
by introduction into cells of short RNA duplexes of 19–23
residues, often containing 2-nucleotide overhangs at the 3V-end
(siRNA). Such siRNAs can either be expressed from vectors
(as individual strands or a single hairpin) or exogenously
delivered (e.g., cationic lipid-mediated). The siRNAs are
recognised by the RISC complex, which is found in the
cytoplasm of cells, and one strand (antisense or guide strand) is
directed to form a duplex with the RNA target, which is
subsequently cleaved by an RNase III-like activity within a
component of RISC.
HIV-1 RNA was an obvious early target for siRNA and
reviews on gene silencing of HIV-1 are now available [74–76].
Many different targets on HIV-1 RNA have been explored and
compared, particularly with respect to the genes coding for
essential proteins. But there are serious difficulties associated
with the ability of HIV-1 to generate mutations that give rise to
resistance [77]. This can include altering the folding of the
HIV-1 RNA genome [78]. As a result gene therapy approaches
are focussing on targeting several regions of the HIV-1 genome
simultaneously, in the hope that the virus may be less able to
escape from such a challenge.
Surprisingly, few papers have described targeting of the
HIV-1 RNA leader. Although an early report appeared
promising on TAR targeting of a 19-mer siRNA duplex in
blocking HIV-1 infection in an acute assay [79], a more recent
study suggests that the TAR target has too tight a secondary
structure for efficient strand invasion and siRNA activity, based
on an expression activity of an adjacent luciferase reporter gene
[80]. An siRNA targeted to the U5 region, which also tails back
into the bottom part of the stem of the poly(A) region, was one
of the least effective in inhibition of HIV-1 in transfected and
infected cells [81]. The siRNA was expressed intracellularly
from a plasmid.
Perhaps, the most encouraging article describes the
evaluation of an siRNA targeted to the highly conserved
18-residue PBS sequence. The well-known availability of this
RNA sequence for interaction with tRNAs as well as its
extremely high sequence conservation of all 18 residues
makes this a prime target for siRNA. Delivery of the PBS-
targeted siRNA by lipofection into SupT1 cells resulted in
substantial reduction in p24 levels when subsequently
infected by HIV-1 NL4-3 strain, resulting in a lag of HIV-1
production over a 15-day period [82]. Similarly, an anti-PBS
siRNA expressed in an adeno-associated virus vector inhib-
ited virus production almost completely for 2 weeks during
extended cell culture. Interestingly, the virus that eventually
broke through did not show any mutation in the PBS target
sequence [82].One advantage of siRNA over antisense approaches is that
within cells the siRNA is thought to be able to remain within
RISC complexes for multiple rounds of RNA cleavage and
therefore effects are often seen for several days in cell culture.
However, not enough is known at present about what off-target
effects might be seen with siRNA if used as an anti-HIV-1
therapeutic. Further, systemic delivery of unmodified siRNA is
unlikely to be an option because of rapid degradation and
clearance. Highly chemically modified RNA would undoubt-
edly be needed [83], in order to allow a sufficient chance to
reach enough target T cells and macrophages to reduce HIV-1
replication. To date there has been very little work published on
the design of chemically modified siRNA suitable for anti-
HIV-1 use with systemic treatment, or on trying to improve
cellular uptake, for example conjugate synthesis. Both of these
topics will need to be addressed before there would be any
hope of proceeding towards possible clinical application.
4. The challenges of oligonucleotides as antivirals and
virucides
The failure of GEM91 in clinical trials was a body blow to
those dedicated to evaluation of oligonucleotides and their
analogues as anti-HIV-1 agents. This failure has undoubtedly
led to the current reluctance by industry to consider such
reagent types again in the context of antiviral agents. Yet all
indications are that GEM 91 was nowhere close to optimal as a
therapeutic chemical entity, particularly because of its non-
sequence-specific effects, even though the target RNA se-
quence at the AUG initiator codon was well chosen. There are
now very promising results in several areas that suggest that the
time is right for further serious efforts to study the potential of
newer oligonucleotide-type materials and their derivatives as
anti-HIV-1 therapeutics.
Steric block oligonucleotides have been shown to have
considerable activity in vivo [48,49]. Further, a steric block
PNA-peptide conjugate appears to have favourable pharmaco-
kinetics in an animal model for Burkitt’s lymphoma and low or
no toxicity [84]. It is not clear as yet as to how PNA-peptides
may enter tumour cells or whether such conjugates will have
sustainable anti-cancer activity, but there appears to be no
intrinsic pharmacological barrier to their further development
as therapeutics. Key issues for use of steric block oligonucleo-
tides as anti-HIV-1 agents are a) to determine the most effective
viral targets where viral escape is minimal, b) to be able to
enhance free cellular uptake and delivery, in order to obtain
high efficacy levels without the non-sequence-specific effects
previously observed with oligonucleotides composed of PS
linkages, such as GEM 91 [37]. As shown in this article, the
viral leader of HIV-1 RNA contains several highly conserved
sequences that are very good candidates for future development
of steric block oligonucleotide, aptamer, or siRNA approaches.
These targets now need to be evaluated head-to-head in long-
term cell culture studies in models of acute and chronic HIV-1
infection with these new oligonucleotide reagent types.
The issue of enhancement of cell uptake and delivery to the
desired intracellular compartment is another crucial aspect.
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most oligonucleotides into cells is by endocytosis. Although
several types of endocytosis have been delineated, it seems that
entrapment in vesicular compartments of some type is the most
likely fate of an oligonucleotide when it is taken up by a cell.
Finding better ways to release the oligonucleotide, at least in
part, from endocytic vesicles to enhance intracellular activity is
now a major preoccupation for those working in this field. For
example, we are currently investigating the anti-HIV-1
activities of a range of steric block oligonucleotides targeted
to TAR containing different chemical backbone types, espe-
cially with a view to obtaining activity via free delivery [63].
PNA–peptide conjugates with their demonstrated antiviral and
virucidal activities look particularly promising in this respect
[68]. SiRNA delivery is still in its infancy and it is hoped that
the promise of the early results against the PBS target [82] can
be transformed into a potential clinical lead by the use of
chemically modified siRNA having good pharmacological
parameters when delivered systemically in vivo. This re-
emerging field, to date mostly involving a small number of
research groups, is now worth more serious consideration by
virologists and pharmacologists interested in developing lead
anti-HIV-1 compounds suitable for clinical evaluation.
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